Daniel A. Walsh, phd

Strategic IP portfolio management guided by technical expertise
and legal insight

Daniel A. Walsh, PhD, focuses on every stage of patent protection for life-science innovations—
from patentability and freedom-to-operate reviews to the preparation, prosecution, and
management of patent portfolios. He has experience advising publicly traded pharmaceutical and
biotechnology companies, venture-backed start-ups, and research institutions, tailoring IP
strategies to each client’s unique business objectives.

Daniel regularly coordinates prosecution across jurisdictions to secure robust, long-lasting
coverage. His drafting and prosecution experience spans a wide spectrum of technologies,
including vaccines, viral vectors, recombinant antibodies, protein therapeutics, gene and cell
therapies, engineered cell implants, CRISPR technologies, diagnostics, nucleic acid amplification
and sequencing technologies, regenerative-medicine, and treatments for cancer, autoimmune
disorders, and infectious diseases.

Daniel received a BS in biology from Indiana University and a JD from the University of
Minnesota. Daniel earned a PhD in immunology from the University of Minnesota, participating
in the interdisciplinary Microbiology, Immunology, and Cancer Biology program. His graduate
research centered on the mechanisms of T cell trafficking in the context of vaccines, infectious
diseases, and cancer. During his PhD, Daniel worked as an intern at the University of Minnesota
Office of Technology Commercialization performing patent searches and due diligence at the
earliest stages of commercialization. Prior to joining McNeill PLLC, Daniel drafted and
prosecuted US and international patent applications for four years at Klarquist Sparkman.

With this breadth of technical insight and a command of evolving U.S. patent law, Daniel
delivers integrated, forward-looking IP strategies that protect and maximize the value of his
clients’ most critical technologies.

Select Publications

“Physiological Microbial Exposure has a Temporally Limited Inhibitory Effect on Lung ILC2 Responses to Allergens in Mice,” Nature Immunology, 23:1703-1713, November 21, 2022 (coauthor).

“The Functional Requirement for CD69 in Establishment of Resident Memory CD8 + T Cells Varies with Tissue Location,” Journal of Immunology, 203:946-955, August 15, 2019 (coauthor).

“The Purinergic Receptor P2RX7 Directs Metabolic Fitness of Long-lived Memory CD8+ T Cells,” Nature,559:264-268, July 4, 2018 (coauthor).

“IL-4 Impairs Wound Healing Potential in the Skin by Repressing Fibronectin Expression,” Journal of
Allergy and Clinical Immunology, 139:142-151, January 2017 (coauthor).

“Th9 Cell Development Requires a BATF-regulated Transcriptional Network,” Journal of Clinical
Investigation, 123:4641-4653, October 8, 2013 (coauthor).